The Mouse Model of Internal Capsule Demyelination: A Novel Tool for Investigating Motor Functional Changes Caused by Demyelination and for Evaluating Drugs That Promote Remyelination

IF 1.6 4区生物学 Q4 CELL BIOLOGY Acta Histochemica Et Cytochemica Pub Date : 2024-02-23 DOI:10.1267/ahc.24-00005

Reiji Yamazaki, Nobuhiko Ohno

{"title":"The Mouse Model of Internal Capsule Demyelination: A Novel Tool for Investigating Motor Functional Changes Caused by Demyelination and for Evaluating Drugs That Promote Remyelination","authors":"Reiji Yamazaki, Nobuhiko Ohno","doi":"10.1267/ahc.24-00005","DOIUrl":null,"url":null,"abstract":"Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system, characterized by remyelination failure and axonal dysfunction. Remyelination by oligodendrocytes is critical for improvement of neurological deficits associated with demyelination. Rodent models of demyelination are frequently used to develop and evaluate therapies for MS. However, a suitable mouse model for assessing remyelination-associated recovery of motor functions is currently unavailable. In this review, we describe the development of the mouse model of internal capsule (IC) demyelination by focal injection of lysolecithin into brain and its application in the evaluation of drugs for demyelinating diseases. This mouse model exhibits motor deficits and subsequent functional recovery accompanying IC remyelination. Notably, this model shows enhancement of functional recovery as well as tissue regeneration when treated with clemastine, a drug that promotes remyelination. The IC demyelination mouse model should contribute to the development of novel drugs that promote remyelination and ameliorate neurological deficits in demyelinating diseases.\n","PeriodicalId":6888,"journal":{"name":"Acta Histochemica Et Cytochemica","volume":null,"pages":null},"PeriodicalIF":1.6000,"publicationDate":"2024-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Histochemica Et Cytochemica","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.1267/ahc.24-00005","RegionNum":4,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system, characterized by remyelination failure and axonal dysfunction. Remyelination by oligodendrocytes is critical for improvement of neurological deficits associated with demyelination. Rodent models of demyelination are frequently used to develop and evaluate therapies for MS. However, a suitable mouse model for assessing remyelination-associated recovery of motor functions is currently unavailable. In this review, we describe the development of the mouse model of internal capsule (IC) demyelination by focal injection of lysolecithin into brain and its application in the evaluation of drugs for demyelinating diseases. This mouse model exhibits motor deficits and subsequent functional recovery accompanying IC remyelination. Notably, this model shows enhancement of functional recovery as well as tissue regeneration when treated with clemastine, a drug that promotes remyelination. The IC demyelination mouse model should contribute to the development of novel drugs that promote remyelination and ameliorate neurological deficits in demyelinating diseases.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

内囊脱髓鞘小鼠模型：研究脱髓鞘引起的运动功能变化和评估促进脱髓鞘药物的新工具

多发性硬化症（MS）是中枢神经系统的一种炎症性脱髓鞘疾病，以再髓鞘化失败和轴突功能障碍为特征。少突胶质细胞的再髓鞘化对改善脱髓鞘引起的神经功能缺损至关重要。脱髓鞘的啮齿动物模型常用于开发和评估多发性硬化症的疗法。然而，目前还没有合适的小鼠模型来评估与再髓鞘化相关的运动功能恢复情况。在这篇综述中，我们介绍了通过向大脑局灶性注射溶血卵磷脂而建立的内囊（IC）脱髓鞘小鼠模型，以及该模型在脱髓鞘疾病药物评估中的应用。这种小鼠模型表现出运动障碍，随后伴随着内囊脱髓鞘的功能恢复。值得注意的是，该模型在使用促进再髓鞘化的药物氯马斯汀（clemastine）治疗后，功能恢复和组织再生均有所增强。集成电路脱髓鞘小鼠模型有助于开发促进脱髓鞘再形成和改善脱髓鞘疾病神经功能缺损的新型药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Acta Histochemica Et Cytochemica 生物-细胞生物学

CiteScore

3.50

自引率

8.30%

发文量

审稿时长

>12 weeks

期刊介绍： Acta Histochemica et Cytochemica is the official online journal of the Japan Society of Histochemistry and Cytochemistry. It is intended primarily for rapid publication of concise, original articles in the fields of histochemistry and cytochemistry. Manuscripts oriented towards methodological subjects that contain significant technical advances in these fields are also welcome. Manuscripts in English are accepted from investigators in any country, whether or not they are members of the Japan Society of Histochemistry and Cytochemistry. Manuscripts should be original work that has not been previously published and is not being considered for publication elsewhere, with the exception of abstracts. Manuscripts with essentially the same content as a paper that has been published or accepted, or is under consideration for publication, will not be considered. All submitted papers will be peer-reviewed by at least two referees selected by an appropriate Associate Editor. Acceptance is based on scientific significance, originality, and clarity. When required, a revised manuscript should be submitted within 3 months, otherwise it will be considered to be a new submission. The Editor-in-Chief will make all final decisions regarding acceptance.